16:46 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Oncologie raises $16.5M for dual U.S.-China strategy

Cancer company Oncologie Ltd. (Cayman Islands) raised $16.5 million in a seed financing led by Pivotal bioVenture Partners China. Nan Fung Life Sciences, China Merchant Bank Investments and Volcanics Ventures also joined the round. Oncologie plans...
21:33 , Jun 7, 2018 |  BC Extra  |  Financial News

Oncologie raises $16.5M for dual U.S.-China strategy

Cancer company Oncologie Ltd. (Cayman Islands) raised $16.5 million in a seed financing led by Pivotal bioVenture Partners China. Nan Fung Life Sciences, China Merchant Bank Investments and Volcanics Ventures also joined the round. Oncologie plans...
20:00 , Feb 16, 2018 |  BC Week In Review  |  Company News

Oncologie purchases bavituximab from Avid

Oncologie Ltd. (Cayman Islands) acquired a phosphatidylserine-targeting program including bavituximab from Avid Bioservices Inc. (NASDAQ:CDMO), formerly Peregrine Pharmaceuticals. Avid, which transitioned to a contract development and manufacturing organization in January, will receive $8 million upfront...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

Bavituximab: Interim Phase III data

Interim data from the double-blind, international Phase III SUNRISE trial in about 582 previously treated patients with stage IIIb/IV non-squamous NSCLC showed that once-weekly IV bavituximab plus docetaxel missed the primary endpoint of improving median...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

Bavituximab: Phase III discontinued

Peregrine discontinued the double-blind, international Phase III SUNRISE trial in about 582 previously treated patients with stage IIIb/IV non-squamous NSCLC after a pre-specified interim analysis by an IDMC showed that once-weekly IV bavituximab plus docetaxel...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Company News

Peregrine, AstraZeneca deal

The companies expanded an August deal and will evaluate Peregrine’s bavituximab with AstraZeneca’s durvalumab in an international Phase II trial in patients with previously treated squamous or non-squamous non-small cell lung cancer (NSCLC). The original...
07:00 , Oct 5, 2015 |  BC Week In Review  |  Company News

Peregrine, AstraZeneca deal

The companies partnered to evaluate Peregrine’s bavituximab with AstraZeneca’s durvalumab ( MEDI4736) to treat multiple solid tumors. Peregrine will conduct a Phase I/Ib trial. Bavituximab, a chimeric mAb against phosphatidylserine, is in Phase...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Company News

Peregrine, Memorial Sloan Kettering deal

Peregrine and Memorial Sloan Kettering partnered to identify treatment combinations based on Peregrine’s phosphatidylserine (PS)-targeting antibody platform to treat cancer. The cancer center will perform research to explore the combination of PS-targeting agents, including...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Bavituximab: Additional Phase I data

Additional data from an U.S. Phase I trial in 13 evaluable patients with HER2-negative metastatic breast cancer showed that IV bavituximab plus paclitaxel led to a median PFS of 7.3 months. Patients received once-weekly 3...